Table 2.
Objective responsesa for all patients and for the acral and mucosal subpopulations (full-analysis set).
|
All Patients N = 102 (%) |
Acral n = 38 |
Mucosal n = 15 |
|
|---|---|---|---|
| CR | 1 (1.0) | 0 (0) | 1 (6.7) |
| PR | 16 (15.7) | 6 (15.8) | 1 (6.7) |
| Objective response rate (CR + PR) | 17 (16.7) | 6 (15.8) | 2 (13.3) |
| SD | 22 (21.6) | 10 (26.3) | 1 (6.7) |
| Disease control rate (CR + PR + SD) | 39 (38.2) | 16 (42.1) | 3 (20.0) |
| Progressive disease | 52 (51.0) | 18 (47.4) | 8 (53.3) |
| No assessment | 11 (10.8) | 4 (10.5) | 4 (26.7) |
CR, complete response; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.
a
Based on RECIST v1.1 per blinded independent central review.